Related Experiment Videos
Current perspectives on beta-receptor antagonists in the treatment of symptomatic ventricular dysfunction
1Department of Medicine, University of North Carolina at Chapel Hill 27599-7075, USA.
Insights
Beta-blockers are effective in treating heart failure by improving ventricular function and reducing mortality. While some patients experience intolerance, most can be successfully managed with these agents, offering significant benefits beyond traditional therapies.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure remains a significant cause of morbidity and mortality despite therapeutic advances.
- Traditional treatments like digitalis, diuretics, and ACE inhibitors do not prevent disease progression in all patients.
- The renin-angiotensin-aldosterone (RAA) axis and autonomic nervous system play critical roles in heart failure pathophysiology.
Purpose of the Study:
- To investigate the efficacy of beta-receptor blocking agents in managing heart failure.
- To explore the role of sympathetic nervous system overactivity in heart failure progression.
Main Methods:
- Review of clinical trials investigating beta-blocker therapy in heart failure patients.
- Analysis of the impact of autonomic nervous system alterations on ventricular dysfunction.
Main Results:
- Pharmacologic suppression of the RAA system shows clinical benefit.
- Excessive sympathetic activity is an early adaptation in heart failure, promoting disease progression.
- Beta-blockers, when carefully titrated, improve ventricular function and symptoms in large-scale studies.
- Preliminary data suggest reductions in mortality and morbidity with beta-blocker use.
Conclusions:
- Beta-blockers are effective in improving heart failure outcomes, including ventricular function, symptoms, and potentially reducing mortality.
- While beta-antagonism intolerance occurs, most patients can tolerate and benefit from beta-blocker therapy.
Abstract:
Even though therapeutic advances have occurred, heart failure is still associated with significant morbidity and mortality. Digitalis, diuretics, and angiotensin-converting enzyme inhibitors have proven effective, but in many patients still do not prevent progressive and debilitating heart failure. Many hormonal factors are involved, but two, the renin-angiotensin-aldosterone (RAA) axis and the autonomic nervous system, apparently are critical in the pathophysiology of progressive ventricular dysfunction. Pharmacologic suppression of the RAA system is associated with significant clinical benefit, suggesting that antagonism of sympathetic nervous activity with beta-receptor-blocking agents might also be efficacious. Major alterations of the autonomic nervous system are characteristic of heart failure, with excessive sympathetic activity one of the earliest adaptations to the condition, and important in promoting the heart failure state and the progression of ventricular dysfunction. Certain beta-antagonists administered by careful and slow up-titration from small starting dosages proved effective in small trials. Large-scale, randomized, placebo-controlled studies continue to document that beta-blockers improve ventricular function and symptoms, and preliminary results suggests mortality and morbidity reductions as well. Although intolerance to beta-antagonism does occur, the majority of patients can be successfully treated with these agents.